{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Assessment of Tofacitinib Usage in the Management of Rheumatoid Arthritis in India (ASSET Survey)

  1. How many rheumatoid arthritis patients do you see in a week? *

  2. Among rheumatoid arthritis patients what is the percentage of patients who have moderately to severely active disease in your practice? *

  3. Which is the most frequently used Conventional Synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) in your clinical practice for the management of rheumatoid arthritis? *

  4. What percentage of rheumatoid arthritis patients do not adequately respond to methotrexate in your practice? *

  5. What is your preferred choice of treatment in the management of moderately to severely active rheumatoid arthritis? *

  6. In which type of rheumatoid arthritis patient, you prefer to prescribe Tofacitinib? (You can select multiple applicable answers) *

  7. Since how long have you been prescribing Tofacitinib in the management of rheumatoid arthritis? *

  8. In which of the following indication do you prefer Tofacitinib over other drugs? *

  9. What factors influence your decision to prescribe Tofacitinib over other DMARDs? (You can select multiple applicable answers)? *

  10. What is your preferred choice among two formulations of Tofacitinib for the management of moderately to severely active rheumatoid arthritis? *

  11. What are the steps do you take to achieve desired therapeutic results with Tofacitinib in your clinical practice in rheumatoid arthritis management? *
  12. Which type of patients you prefer to put on Tofacitinib 11mg extended release formulation? *
  13. Which of the following essential monitoring you conduct for Tofacitinib treatment? *

  14. Have you noticed any specific patient populations that responds better to Tofacitinib? *

  15. How is your experience with Tofacitinib in patients who have failed to other DMARDs? *

  16. How do you consider Tofacitinib in your overall treatment approach for the treatment of rheumatoid arthritis? *

  17. How long do you continue Tofacitinib in your patients (Without much concern about side effects)? *

  18. How do you assess treatment response with Tofacitinib in your patients? *

  19. Do you prefer to use Tofacitinib as a monotherapy (without combination with methotrexate) in the management of rheumatoid arthritis? *

  20. How long does it take to get remission on Tofacitinib 5 mg twice daily/11 mg once daily in moderately to severely active rheumatoid arthritis? *

  21. When do you shift the dose of Tofacitinib 5 mg BID to 5 mg OD in the management of moderately to severely active rheumatoid arthritis? *
  22. How would you rate efficacy of Tofacitinib in comparison to biological DMARDs in the management of rheumatoid arthritis? *

  23. What are the situations according to you when Tofacitinib dose adjustment is required? *
  24. What are your thoughts on the cost-effectiveness of Tofacitinib compared to other treatment options? *

  25. According to you what are the major limiting factors while considering Tofacitinib as a treatment of choice in rheumatoid arthritis management? *

  26. Have you encountered any challenges in terms of patient adherence with Tofacitinib treatment? *

  27. What are the key counselling points you provide to patients after starting Tofacitinib treatment? *

  28. Have you encountered any instances of inadequate response with Tofacitinib? *

  29. What strategies do you employ to optimize patient outcomes with Tofacitinib? *

  30. What would be your preference for gathering additional information about Tofacitinib? *